carbamates has been researched along with Chronic Kidney Diseases in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 8.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited." | 8.12 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS, 2022) |
| "In the C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic kidney disease resulted in a high rate of virological cure compared with placebo." | 5.24 | Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial ( Arduino, JM; Barr, E; Bruchfeld, A; Greaves, W; Hwang, P; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J, 2017) |
| "Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min." | 4.12 | Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R). ( Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S, 2022) |
| "Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited." | 4.12 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. ( Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS, 2022) |
| "Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected patients with or without compensated liver cirrhosis." | 3.96 | Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4. ( Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Blaszkowska, M; Buczyńska, I; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D, 2020) |
| "We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b." | 3.96 | Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. ( Iliescu, EL; Mercan-Stanciu, A; Toma, L, 2020) |
| "The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin." | 3.91 | Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort. ( Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z, 2019) |
| " The most common adverse event was anemia, which was more common in group 2." | 1.91 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease. ( Ammar, I; Doss, W; El Raziky, M; El-Sayed, M; Elakel, W; Elsaeed, K; Elserafy, M; Elshazly, Y; Fayad, T; Hassany, M; Korany, M; Mahrous, M; Mehrez, M; Saad, Y; Salama, R; Zaki, A, 2023) |
| "7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision." | 1.51 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. ( Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019) |
| "In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs)." | 1.51 | Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia. ( Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J, 2019) |
| " RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily." | 1.48 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. ( Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018) |
| "Homocitrulline (HCit) is a carbamylation-derived product (CDP) that has been identified as a valuable biomarker of morbidity and mortality in patients with chronic kidney disease (CKD)." | 1.43 | Homocitrulline as marker of protein carbamylation in hemodialyzed patients. ( Desmons, A; Fadel, F; Gillery, P; Jaisson, S; Kazes, I; Millart, H; Oudart, JB; Rieu, P; Santos-Weiss, IC; Touré, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 24 (75.00) | 24.3611 |
| 2020's | 8 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sayed, M | 1 |
| Elserafy, M | 2 |
| El Raziky, M | 1 |
| Elakel, W | 1 |
| Saad, Y | 2 |
| Fayad, T | 1 |
| Korany, M | 1 |
| Mehrez, M | 1 |
| Salama, R | 1 |
| Mahrous, M | 1 |
| Zaki, A | 1 |
| Hassany, M | 1 |
| Ammar, I | 1 |
| Elsaeed, K | 2 |
| Elshazly, Y | 2 |
| Doss, W | 1 |
| Londoño, MC | 4 |
| Riveiro-Barciela, M | 1 |
| Ahumada, A | 1 |
| Muñoz-Gómez, R | 1 |
| Roget, M | 1 |
| Devesa-Medina, MJ | 1 |
| Serra, MÁ | 1 |
| Navascués, CA | 1 |
| Baliellas, C | 1 |
| Aldamiz-Echevarría, T | 1 |
| Gutiérrez, ML | 1 |
| Polo-Lorduy, B | 1 |
| Carmona, I | 1 |
| Benlloch, S | 1 |
| Bonet, L | 1 |
| García-Samaniego, J | 1 |
| Jiménez-Pérez, M | 1 |
| Morán-Sánchez, S | 1 |
| Castro, Á | 1 |
| Delgado, M | 1 |
| Gea-Rodríguez, F | 1 |
| Martín-Granizo, I | 1 |
| Montes, ML | 1 |
| Morano, L | 1 |
| Castaño, MA | 1 |
| de Los Santos, I | 1 |
| Laguno, M | 2 |
| Losa, JE | 1 |
| Montero-Alonso, M | 1 |
| Rivero, A | 1 |
| de Álvaro, C | 1 |
| Manzanares, A | 1 |
| Mallolas, J | 2 |
| Barril, G | 1 |
| González-Parra, E | 1 |
| García-Buey, L | 1 |
| Wiegand, J | 2 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 2 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 2 |
| Manns, MP | 1 |
| Zeuzem, S | 2 |
| Berg, T | 2 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Zarębska-Michaluk, D | 1 |
| Jaroszewicz, J | 1 |
| Buczyńska, I | 1 |
| Simon, K | 1 |
| Lorenc, B | 1 |
| Tudrujek-Zdunek, M | 1 |
| Tomasiewicz, K | 1 |
| Sitko, M | 1 |
| Garlicki, A | 1 |
| Janczewska, E | 1 |
| Dybowska, D | 1 |
| Halota, W | 1 |
| Pawłowska, M | 1 |
| Pabjan, P | 1 |
| Mazur, W | 1 |
| Czauż-Andrzejuk, A | 1 |
| Berak, H | 1 |
| Horban, A | 1 |
| Socha, Ł | 1 |
| Klapaczyński, J | 1 |
| Piekarska, A | 1 |
| Blaszkowska, M | 1 |
| Belica-Wdowik, T | 1 |
| Dobracka, B | 1 |
| Tronina, O | 1 |
| Deroń, Z | 1 |
| Białkowska-Warzecha, J | 1 |
| Laurans, Ł | 1 |
| Flisiak, R | 1 |
| Choi, DT | 1 |
| Puenpatom, A | 1 |
| Yu, X | 1 |
| Erickson, KF | 1 |
| Kanwal, F | 1 |
| El-Serag, HB | 1 |
| Kramer, JR | 1 |
| Iliescu, EL | 1 |
| Mercan-Stanciu, A | 1 |
| Toma, L | 1 |
| Huang, CF | 1 |
| Yu, ML | 1 |
| Stein, K | 1 |
| Stoehr, A | 1 |
| Teuber, G | 1 |
| Naumann, U | 1 |
| John, C | 1 |
| Heyne, R | 1 |
| Niederau, C | 1 |
| Li, C | 1 |
| Liang, J | 1 |
| Xiang, H | 1 |
| Chen, H | 1 |
| Tian, J | 1 |
| Liu, CH | 1 |
| Chen, CY | 1 |
| Su, WW | 1 |
| Tseng, KC | 1 |
| Lo, CC | 1 |
| Liu, CJ | 1 |
| Chen, JJ | 1 |
| Peng, CY | 1 |
| Shih, YL | 1 |
| Yang, SS | 1 |
| Huang, CS | 1 |
| Huang, KJ | 1 |
| Chang, CY | 1 |
| Tsai, MC | 1 |
| Kao, WY | 1 |
| Fang, YJ | 1 |
| Chen, PY | 1 |
| Su, PY | 1 |
| Tseng, CW | 1 |
| Huang, JJ | 1 |
| Lee, PL | 1 |
| Lai, HC | 1 |
| Hsieh, TY | 1 |
| Chang, CH | 1 |
| Huang, YJ | 1 |
| Lee, FJ | 1 |
| Chang, CC | 1 |
| Kao, JH | 1 |
| Delanghe, S | 1 |
| Moerman, A | 1 |
| Pletinck, A | 1 |
| Schepers, E | 1 |
| Glorieux, G | 1 |
| Van Biesen, W | 1 |
| Delanghe, JR | 1 |
| Speeckaert, MM | 1 |
| Bruchfeld, A | 2 |
| Roth, D | 3 |
| Martin, P | 3 |
| Nelson, DR | 2 |
| Pol, S | 2 |
| Monsour, H | 2 |
| Silva, M | 2 |
| Hwang, P | 1 |
| Arduino, JM | 1 |
| Robertson, M | 2 |
| Nguyen, BY | 2 |
| Wahl, J | 2 |
| Barr, E | 2 |
| Greaves, W | 3 |
| Morisawa, N | 2 |
| Koshima, Y | 2 |
| Kuriyama, S | 2 |
| Matsuyama, M | 1 |
| Hayashi, N | 1 |
| Satoh, JI | 2 |
| Amemiya, M | 2 |
| Yokoo, T | 2 |
| Nicolas, C | 1 |
| Jaisson, S | 3 |
| Gorisse, L | 2 |
| Tessier, FJ | 1 |
| Niquet-Léridon, C | 1 |
| Jacolot, P | 1 |
| Pietrement, C | 2 |
| Gillery, P | 3 |
| Sanai, FM | 1 |
| Alghamdi, AS | 1 |
| Afghani, AA | 1 |
| Alswat, K | 1 |
| AlZanbagi, A | 1 |
| Alghamdi, MN | 1 |
| AlMousa, A | 1 |
| Aseeri, M | 1 |
| Assiri, AM | 1 |
| Babatin, MA | 1 |
| Goel, A | 1 |
| Bhadauria, DS | 1 |
| Kaul, A | 1 |
| Verma, P | 1 |
| Mehrotra, M | 1 |
| Gupta, A | 1 |
| Sharma, RK | 1 |
| Rai, P | 1 |
| Aggarwal, R | 1 |
| Nayak, SL | 1 |
| Gupta, E | 1 |
| Kataria, A | 1 |
| Sarin, SK | 1 |
| Abdel-Razek, W | 1 |
| Waked, I | 1 |
| Maduell, F | 1 |
| Belmar, L | 1 |
| Ugalde, J | 1 |
| Martínez-Rebollar, M | 1 |
| Ojeda, R | 1 |
| Arias, M | 1 |
| Rodas, L | 1 |
| Rossi, F | 1 |
| Llovet, LP | 1 |
| González, LN | 1 |
| Ogawa, E | 1 |
| Furusyo, N | 1 |
| Azuma, K | 1 |
| Nakamuta, M | 1 |
| Nomura, H | 1 |
| Dohmen, K | 1 |
| Satoh, T | 1 |
| Kawano, A | 1 |
| Koyanagi, T | 1 |
| Ooho, A | 1 |
| Takahashi, K | 1 |
| Kato, M | 1 |
| Shimoda, S | 1 |
| Kajiwara, E | 1 |
| Hayashi, J | 1 |
| Fabrizi, F | 1 |
| Negro, F | 1 |
| Bondin, M | 1 |
| Cacoub, P | 1 |
| Örmeci, N | 1 |
| Sezgin, O | 1 |
| Karaali, R | 1 |
| Aygen, B | 1 |
| Turan, D | 1 |
| Yaras, S | 1 |
| Erdem, İ | 1 |
| Yildiz, O | 1 |
| Karakaya, F | 1 |
| Ateş, K | 1 |
| Asiller, ÖÖ | 1 |
| Said, M | 1 |
| Omar, H | 1 |
| Soliman, Z | 1 |
| Dabes, H | 1 |
| Hamed, S | 1 |
| Opdebeeck, B | 1 |
| Maudsley, S | 1 |
| Azmi, A | 1 |
| De Maré, A | 1 |
| De Leger, W | 1 |
| Meijers, B | 1 |
| Verhulst, A | 1 |
| Evenepoel, P | 1 |
| D'Haese, PC | 2 |
| Neven, E | 1 |
| Behets, GJ | 1 |
| Dams, G | 1 |
| Damment, SJ | 1 |
| De Broe, ME | 1 |
| Liapakis, A | 1 |
| Hassanein, T | 1 |
| Zamor, PJ | 1 |
| Zuckerman, E | 1 |
| Wan, S | 1 |
| Jackson, B | 1 |
| Alric, L | 1 |
| Bonnet, D | 1 |
| Kazes, I | 1 |
| Desmons, A | 1 |
| Fadel, F | 1 |
| Oudart, JB | 1 |
| Santos-Weiss, IC | 1 |
| Millart, H | 1 |
| Touré, F | 1 |
| Rieu, P | 1 |
| Maruyama, Y | 1 |
| Hachicha, M | 1 |
| Botta-Fridlund, D | 1 |
| Elbasha, E | 1 |
| Nwankwo, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease[NCT02092350] | Phase 2/Phase 3 | 237 participants (Actual) | Interventional | 2014-03-17 | Completed | ||
| Pharmacokinetics of Low-dose Sofosbuvir in Dialysis-dependent Patients With Hepatitis C Virus Infection[NCT03883698] | Phase 3 | 30 participants (Actual) | Interventional | 2019-03-15 | Completed | ||
| Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ?[NCT04719338] | 30 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| An Open-label, Phase I, One-dose, One-meal, Balance Study Comparing the Absorption of Dietary Phosphorus When Administering FOSRENOL® (Lanthanum Carbonate) or RENVELA® (Sevelamer Carbonate) in Healthy Adult Volunteers[NCT00875017] | Phase 1 | 31 participants (Actual) | Interventional | 2009-04-20 | Completed | ||
| Open-Labeled Trial Of Direct-Acting Antiviral Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors[NCT02743897] | Phase 1/Phase 2 | 62 participants (Actual) | Interventional | 2016-05-01 | Completed | ||
| A Prospective Cohort Study to Improve HCV Care Using Multidisciplinary Approach to the Treatment of Chronic Hepatitis C in Dialysis Patients: The MATCH-D Study[NCT03791814] | Phase 4 | 0 participants (Actual) | Interventional | 2019-01-01 | Withdrawn (stopped due to The study was stopped due to difficulty in identifying potential patients.) | ||
| "Real World Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring"[NCT03365635] | Phase 4 | 6 participants (Actual) | Interventional | 2019-09-22 | Completed | ||
| Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors[NCT03146741] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group. (NCT02092350)
Timeframe: Up to Week 12
| Intervention | Participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 0 |
| Deferred Treatment | 5 |
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. This analysis includes the Immediate Treatment + Intensive PK group and the placebo treatment period for the Deferred Treatment group. (NCT02092350)
Timeframe: Up to Week 14
| Intervention | Participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 93 |
| Deferred Treatment | 96 |
SVR12 was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) lower than the limit of quantification (LLoQ) 12 weeks after completing study therapy. HCV RNA was measured using the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0®, which has a LLoQ of 15 IU/mL. (NCT02092350)
Timeframe: Week 24 (Immediate Treatment + Intensive PK) or Week 40 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 99.1 |
| Deferred Treatment | 98.0 |
SVR24 was defined as HCV RNA
Timeframe: Week 36 (Immediate Treatment + Intensive PK) or Week 52 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 97.4 |
| Deferred Treatment Group | 98.0 |
SVR4 was defined as HCV RNA
Timeframe: Week 16 (Immediate Treatment + Intensive PK) or Week 32 (Deferred Treatment)
| Intervention | Percentage of participants (Number) |
|---|---|
| Immediate Treatment + Intensive PK | 100.00 |
| Deferred Treatment Group | 99.0 |
Net Calcium Absorption (Lanthanum carbonate period) = Calcium ingested in meal minus (Rectal effluent calcium after Lanthanum carbonate + meal minus Rectal effluent calcium after fasting). Net Calcium Absorption (Sevelamer Carbonate period) = Calcium ingested in meal minus (Rectal effluent calcium after Sevelamer carbonate + meal minus Rectal effluent calcium after fasting). Net Calcium Absorption (Meal only period) = Calcium ingested in meal minus (Rectal effluent calcium after meal only minus Rectal effluent calcium after fasting). (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 49.46 |
| Sevelamer Carbonate | 70.13 |
| Meal Only | 65.02 |
Net phosphorous absorption (Lanthanum carbonate period) = phosphorous ingested in meal minus (Rectal effluent phosphorous after Lanthanum carbonate + meal minus Rectal effluent phosphorous after fasting). Net phosphorous absorption (Sevelamer Carbonate period) = Phosphorous ingested in meal minus (Rectal effluent phosphorous after Sevelamer carbonate + meal minus Rectal effluent phosphorous after fasting). Net phosphorous absorption (Meal only period) = Phosphorous ingested in meal minus (Rectal effluent phosphorous after meal only minus Rectal effluent phosphorous after fasting). (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 156.03 |
| Sevelamer Carbonate | 221.78 |
| Meal Only | 281.68 |
Net Phosphorous Binding (Lanthanum carbonate period) = Rectal effluent phosphorous after Lanthanum carbonate + meal minus Rectal effluent phosphorous after meal only. Net Phosphorous Binding (Sevelamer carbonate period) = Rectal effluent phosphorous after Sevelamer carbonate + meal minus Rectal effluent phosphorous after meal only. (NCT00875017)
Timeframe: 10 hours post-dose
| Intervention | mg (Least Squares Mean) |
|---|---|
| Lanthanum Carbonate | 135.05 |
| Sevelamer Carbonate | 63.15 |
Subjects with post-treatment sustained virologic response (SVR) = Number of subjects with negative HCV RNA 12 weeks after completing therapy / number of subjects treated post-kidney transplantation (NCT02743897)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 62 |
Number of subjects with major adverse events attributable to HCV therapy in post-kidney transplant (NCT02743897)
Timeframe: Baseline to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Direct-acting Antiviral Treatment for HCV | 1 |
The number of participants for whom their third party insurance approved payment of the DAA (study drug) (NCT03365635)
Timeframe: Within one month of last patient enrolled
| Intervention | Participants (Count of Participants) |
|---|---|
| Genotype 1a -Rx Naive -no NS5A Polymorph | 0 |
| Genotype 1b - Rx Naive | 0 |
Absence of HCV by viral RNA quantitation at 12 weeks post treatment (NCT03365635)
Timeframe: 12 weeks after completion of Elbasivir/Grazoprevir treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Genotype 1a -Rx Naive -no NS5A Polymorph | 3 |
| Genotype 1a, Rx Naive + NS5A Polymorph | 0 |
| Genotype 1b - Rx Naive | 1 |
| Genotype 1a/1b -Prior INF or NS3/4A | 0 |
| Genotype4 - Treatment Naive | 0 |
The primary analysis will be based on a calculation of SVR rates (number of subjects with SVR; negative HCV RNA after completing Zepatier therapy) / (number of subjects treated with Zepatier post-heart transplantation) (NCT03146741)
Timeframe: Baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 9 |
(NCT03146741)
Timeframe: Baseline to 52 weeks
| Intervention | Severe adverse event (Number) |
|---|---|
| Zepatier (Grazoprevir 100mg and Elbasvir 50 mg) | 0 |
2 reviews available for carbamates and Chronic Kidney Diseases
| Article | Year |
|---|---|
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofur | 2018 |
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Combinations; Dr | 2016 |
3 trials available for carbamates and Chronic Kidney Diseases
27 other studies available for carbamates and Chronic Kidney Diseases
| Article | Year |
|---|---|
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
Topics: Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis | 2023 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Ther | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Comor | 2020 |
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Ther | 2020 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Thera | 2020 |
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolid | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropa | 2022 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates | 2020 |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combi | 2022 |
Quantification of carbamylated albumin in serum based on capillary electrophoresis.
Topics: Adult; Aged; Carbamates; Diabetic Nephropathies; Electrophoresis, Capillary; Female; Humans; Male; M | 2017 |
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; | 2017 |
Carbamylation is a competitor of glycation for protein modification in vivo.
Topics: Albumins; Animals; Blood Glucose; Blood Proteins; Carbamates; Cyanates; Diabetes Mellitus, Experimen | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug | 2018 |
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Topics: Adult; Antiviral Agents; Carbamates; Comorbidity; Dose-Response Relationship, Drug; Drug Monitoring; | 2019 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combinat | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Ma | 2018 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Fe | 2019 |
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cohort Studies; C | 2018 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropan | 2019 |
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt | 2019 |
Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance.
Topics: Animals; Biological Products; Biopsy, Needle; Carbamates; Disease Models, Animal; Glucose Intoleranc | 2019 |
Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD.
Topics: Animals; Carbamates; Collagen; Disease Models, Animal; Extracellular Matrix; Female; Kinetics; Mice; | 2013 |
Homocitrulline as marker of protein carbamylation in hemodialyzed patients.
Topics: Biomarkers; Carbamates; Citrulline; Hemoglobin A; Humans; Longitudinal Studies; Renal Dialysis; Rena | 2016 |
Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; | 2017 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Hum | 2016 |
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclo | 2017 |